Bausch Health Companies (NYSE:BHC - Get Free Report) is expected to be posting its quarterly earnings results after the market closes on Wednesday, February 19th. Analysts expect Bausch Health Companies to post earnings of $1.65 per share and revenue of $2.51 billion for the quarter. Individual interested in participating in the company's earnings conference call can do so using this link.
Shares of BHC opened at $6.38 on Wednesday. The company has a market capitalization of $2.31 billion, a price-to-earnings ratio of -13.29, a P/E/G ratio of 0.34 and a beta of 0.68. The business's 50-day moving average is $7.59 and its 200-day moving average is $7.46. Bausch Health Companies has a fifty-two week low of $3.96 and a fifty-two week high of $11.46.
A number of research firms have issued reports on BHC. Jefferies Financial Group reiterated a "hold" rating and issued a $8.00 target price (down previously from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. StockNews.com raised shares of Bausch Health Companies from a "hold" rating to a "buy" rating in a research note on Friday, October 25th. Royal Bank of Canada reduced their price objective on Bausch Health Companies from $11.00 to $10.00 and set a "sector perform" rating for the company in a research report on Thursday, January 30th. Finally, Evercore ISI upgraded Bausch Health Companies to a "hold" rating in a research note on Tuesday, October 15th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat.com, Bausch Health Companies has a consensus rating of "Hold" and a consensus price target of $7.42.
View Our Latest Report on BHC
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.